14
Participants
Start Date
February 28, 2009
Primary Completion Date
July 31, 2014
Study Completion Date
July 31, 2029
CD19CAR-28-zeta T cells
"Intravenous injection~Dose Level 1:~CD19CAR-28zeta - 2x10\^7 cells/m\^2~Dose Level 2:~CD19CAR-28zeta - 1 x10\^8 cells/m\^2~Dose Level 3:~CD19CAR-28zeta - 2x10\^8 cells/m\^2"
Ipilimumab
For patients with intermediate or low grade leukemia/lymphoma, patients may receive ipilimumab once during the week 2 visit after the T cell infusion.
Houston Methodist Hospital, Houston
Texas Children's Hospital, Houston
The Methodist Hospital Research Institute
OTHER
Center for Cell and Gene Therapy, Baylor College of Medicine
OTHER
Baylor College of Medicine
OTHER